PE20231369A1 - Combinaciones para el tratamiento del cancer - Google Patents

Combinaciones para el tratamiento del cancer

Info

Publication number
PE20231369A1
PE20231369A1 PE2023000162A PE2023000162A PE20231369A1 PE 20231369 A1 PE20231369 A1 PE 20231369A1 PE 2023000162 A PE2023000162 A PE 2023000162A PE 2023000162 A PE2023000162 A PE 2023000162A PE 20231369 A1 PE20231369 A1 PE 20231369A1
Authority
PE
Peru
Prior art keywords
combinations
compound
relates
cancer
treatment
Prior art date
Application number
PE2023000162A
Other languages
English (en)
Spanish (es)
Inventor
Gisela Schwab
Christian Scheffold
Colin Chong
Ssucheng Jeff Hsu
Peter Lamb
Peiwen Yu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20231369A1 publication Critical patent/PE20231369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2023000162A 2020-07-31 2021-07-29 Combinaciones para el tratamiento del cancer PE20231369A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063059601P 2020-07-31 2020-07-31
US202063113556P 2020-11-13 2020-11-13
US202163148921P 2021-02-12 2021-02-12
PCT/US2021/043699 WO2022026706A1 (en) 2020-07-31 2021-07-29 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
PE20231369A1 true PE20231369A1 (es) 2023-09-07

Family

ID=77431400

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000162A PE20231369A1 (es) 2020-07-31 2021-07-29 Combinaciones para el tratamiento del cancer

Country Status (17)

Country Link
US (1) US12673052B2 (enExample)
EP (1) EP4188376A1 (enExample)
JP (2) JP7847576B2 (enExample)
KR (1) KR20230059792A (enExample)
CN (1) CN116437954A (enExample)
AU (1) AU2021318134A1 (enExample)
BR (1) BR112023001792A2 (enExample)
CA (1) CA3186517A1 (enExample)
CL (1) CL2023000289A1 (enExample)
CO (1) CO2023001561A2 (enExample)
CR (1) CR20230052A (enExample)
GE (1) GEAP202616896A (enExample)
IL (1) IL300151A (enExample)
MX (1) MX2023001298A (enExample)
PE (1) PE20231369A1 (enExample)
PH (1) PH12023550160A1 (enExample)
WO (1) WO2022026706A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
CN115398554A (zh) * 2020-04-29 2022-11-25 雀巢产品有限公司 用于在患有精子病症的个体中提供生育能力增强饮食推荐的系统和方法
CN115398561A (zh) * 2020-04-29 2022-11-25 雀巢产品有限公司 用于在患有低睾酮的个体中提供生育能力增强饮食推荐的系统和方法
KR20250029015A (ko) * 2022-03-07 2025-03-04 사노피-아벤티스 유.에스. 엘엘씨 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도
US20250228863A1 (en) * 2022-04-08 2025-07-17 Global Cancer Technology, Inc. Methods and Products to Screen and Treat Glioblastoma Multiforme and Other Cancers, Including Breast Cancers, Using A Combination of PI3KINASE Inhibitors With Checkpoint Inhibitors
CN120390641A (zh) * 2022-10-19 2025-07-29 西雅图儿童医院（Dba西雅图儿童研究所） 采用靶向小分子和抗靶向car t细胞的治疗方法
WO2024173376A2 (en) * 2023-02-13 2024-08-22 LAVA Therapeutics N.V. Combination therapy comprising multispecific gamma delta tcr antibodies
EP4450972A1 (en) * 2023-04-21 2024-10-23 Fundación Instituto de Investigación Sanitaria de Santiago de Compostela In vitro method for predicting cancer patient response to pd-1 and/or pd-l1 inhibitors
CN117285533B (zh) * 2023-11-24 2024-01-30 四川省医学科学院·四川省人民医院 CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物
KR20260016691A (ko) * 2024-07-25 2026-02-04 서울대학교산학협력단 Tpst2 억제제 또는 ifngr1의 황산화 억제제를 포함하는 암의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
AU2017336547A1 (en) 2016-09-27 2019-05-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating urothelial carcinoma and other genitourinary malignancies using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA126970C2 (uk) 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy

Also Published As

Publication number Publication date
KR20230059792A (ko) 2023-05-03
US12673052B2 (en) 2026-07-07
US20230301979A1 (en) 2023-09-28
WO2022026706A1 (en) 2022-02-03
CN116437954A (zh) 2023-07-14
AU2021318134A1 (en) 2023-03-02
JP2023536264A (ja) 2023-08-24
IL300151A (en) 2023-03-01
JP2026099954A (ja) 2026-06-18
MX2023001298A (es) 2023-02-22
CO2023001561A2 (es) 2023-02-16
CL2023000289A1 (es) 2023-09-01
EP4188376A1 (en) 2023-06-07
BR112023001792A2 (pt) 2023-04-11
TW202220654A (zh) 2022-06-01
CA3186517A1 (en) 2022-02-03
JP7847576B2 (ja) 2026-04-17
GEAP202616896A (en) 2026-04-27
PH12023550160A1 (en) 2023-09-18
CR20230052A (es) 2023-04-11

Similar Documents

Publication Publication Date Title
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
PY2126213A (es) Compuestos y métodos para el tratamiento de covid-19
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
CL2021002965A1 (es) Compuestos antivirales que contienen nitrilo.
BR112023021913A2 (pt) Tratamento de câncer com inibidor de raf
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CO2021015624A2 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2019006830A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
BR112015022820A8 (pt) ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit
CO2022000270A2 (es) Inhibidores de enzimas
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
DOP2024000242A (es) Compuestos aromáticos que contienen boro y análogos de insulina relacionados
CO2021004004A2 (es) Composición tópica inyectable
CL2024002542A1 (es) Uso de inhibidor de captación triple para el tratamiento de la depresión atípica
CL2025003405A1 (es) Tratamiento combinado.
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
CL2025000383A1 (es) Combinaciones antineoplásicas que comprenden tratamiento dirigido.
UY40482A (es) Composición líquida de dalbavancina.
UY40481A (es) Composición líquida de dalbavancina
ECSP23075535A (es) Compuestos cíclicos y métodos de uso